Chatham Capital Group, Inc. Amgen Inc Transaction History

Chatham Capital Group, Inc.

$601 Million
Q3 2024

A detailed history of Chatham Capital Group, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Chatham Capital Group, Inc. holds 1,529 shares of AMGN stock, worth $428,227. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,529

Previous 1,519 0.66%

Holding current value

$428,227

Previous $474,000 3.8%

% of portfolio

0.08%

Previous 0.08%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$309.38 - $337.38 $3,093 - $3,373	10 Added 0.66%	1,529 $492,000
Q3 2023 Oct 25, 2023	BUY	$218.65 - $271.46 $1,967 - $2,443	9 Added 0.6%	1,519 $408,000
Q2 2023 Jul 13, 2023	SELL	$214.27 - $253.37 $3,428 - $4,053	-16 Reduced 1.05%	1,510 $335,000
Q2 2022 Aug 02, 2022	BUY	$230.71 - $256.74 $2,768 - $3,080	12 Added 0.79%	1,526 $371,000
Q3 2021 Oct 13, 2021	SELL	$212.27 - $248.7 $19,528 - $22,880	-92 Reduced 5.73%	1,514 $322,000
Q4 2020 Jan 27, 2021	BUY	$216.38 - $257.67 $16,228 - $19,325	75 Added 4.9%	1,606 $369,000
Q2 2020 Jul 20, 2020	SELL	$197.81 - $242.74 $17,605 - $21,603	-89 Reduced 5.49%	1,531 $361,000
Q1 2019 May 09, 2019	SELL	$180.87 - $203.88 $36,174 - $40,776	-200 Reduced 10.99%	1,620 $308,000
Q4 2018 Feb 06, 2019	SELL	$178.4 - $208.25 $1,962 - $2,290	-11 Reduced 0.6%	1,820 $354,000
Q2 2018 Jul 30, 2018	BUY	$166.05 - $186.51 $15,276 - $17,158	92 Added 5.29%	1,831 $338,000
Q4 2017 Feb 01, 2018	SELL	$168.79 - $188.59 $92,834 - $103,724	-550 Reduced 24.03%	1,739 $302,000
Q2 2017 Aug 09, 2017	BUY	N/A	2,289	2,289 $394,000

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chatham Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chatham Capital Group, Inc. with notifications on news.

Account

Chatham Capital Group, Inc. Amgen Inc Transaction History